Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anavex Life Sciences Corp. (AVXL)
USD2.45
+0.02 (+0.99%)
US NASDAQ Healthcare Biotechnology
Address
51 West 52nd Street 10019
New York City, NY, US
New York City, NY, US
CEO
Christopher U. Missling
Website
anavex.com
IPO
2006-08-02
CIK 1314052 ISIN US0327973006
Also trades on
London Stock Exchange · 0HFR.L (USD)
NASDAQ Global Select · AVXL (USD)
Description
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.45
+0.02 (+0.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.12
Float Shares
89.78M
Free Float %
96.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.56% | -8.38% | +3.73% | -21.94% | -55.65% | -14.04% | -64.21% | -66.37% | -70.38% | -23.50% | -61.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
2.45
Low
11.00
+348.2%
Consensus
11.00
+348.2%
Median
11.00
+348.2%
High
11.00
+348.2%
DCF (Unlevered)
1.17
-52.5%
DCF (Levered)
1.20
-51.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
11.00
+348.2%
|
Quality scores
Altman Z-Score
22.77
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-3.9% Q4'25: +54.4% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +528.7% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+2.2% ★ Q4'25: +5.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 2 Rev. Ana. 1 EPS Ana. |
Sep 2027 2 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 9.40M (-100.0%)
|
—
est: 14.38M (-100.0%)
|
776.00M
776.00M – 776.00M
+5,297.1% YoY
|
1.21B
1.21B – 1.21B
+55.9% YoY
|
348.57M
348.57M – 348.57M
-71.2% YoY
|
713.06M
713.06M – 713.06M
+104.6% YoY
|
885.11M
885.11M – 885.11M
+24.1% YoY
|
| EBITDA |
-43.00M
|
-46.38M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-43.00M
|
-46.38M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-43.00M
est: -46.34M (+7.2%)
|
-46.38M
est: -49.18M (+5.7%)
|
-27.86M
-27.86M – -27.86M
+43.4% YoY
|
-12.14M
-12.14M – -12.14M
+56.4% YoY
|
193.53M
193.53M – 193.53M
+1,694.6% YoY
|
397.45M
397.45M – 397.45M
+105.4% YoY
|
446.06M
446.06M – 446.06M
+12.2% YoY
|
| SGA |
11.04M
|
13.82M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.52
est: -0.54 (+4.3%)
|
-0.54
est: -0.58 (+6.4%)
|
-0.33
-0.33 – -0.33
+43.4% YoY
|
-0.14
-0.14 – -0.14
+56.4% YoY
|
2.27
2.27 – 2.27
+1,694.6% YoY
|
4.66
4.66 – 4.66
+105.4% YoY
|
5.23
5.23 – 5.23
+12.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-30.38M
OE per share TTM
-0.44
Owner's Yield
-11.15%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-0.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
76
Total invested
27.65M
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 5.26M | 6.90% | 5.20M | — | 5.26M | — | HC | Delaware | 2022-02-03 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 3.84M | 5.05% | — | — | 3.65M | — | IA | Pennsylvania | 2022-02-09 | ↗ |
| 3 | STATE STREET CORPORATION | 3.83M | 5.04% | — | 3.71M | — | 3.83M | HC | — | 2022-02-09 | ↗ |
| 4 | DAFNA Capital Management, LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2016-02-16 | ↗ |
| 5 | Fariba Ghodsian | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2016-02-16 | ↗ |
| 6 | Nathan Fischel | — | 0.00% | — | — | — | — | HC, IN | Austria citizen (U.S. permanent resident) | 2016-02-16 | ↗ |
| 7 | Park West Asset Management LLC | — | 0.00% | — | — | — | — | IA | (4) Citizenship or Place of Organization | 2021-02-16 | ↗ |
| 8 | Park West Investors Master Fund, Limited | — | 0.00% | — | — | — | — | CO | (4) Citizenship or Place of Organization | 2021-02-16 | ↗ |
| 9 | Peter S. Park | — | 0.00% | — | — | — | — | IN | (4) Citizenship or Place of Organization | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
76
-121 vs prev Q
New positions
10
Closed positions
120
Increased
39
Reduced
18
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 7.53M +337.9K (+4.7%) | 26.79M -37.2M (-58.1%) | 8.45% +0.034 pp | 0.00% -0.001 pp | USD5.86 -39.2% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 5.03M -76.0K (-1.5%) | 17.90M -27.5M (-60.6%) | 5.65% -0.330 pp | 0.00% 0.000 pp | USD7.90 -54.9% | 41 qtrs — |
| 3 | STATE STREET CORP | 4.38M +1.1M (+33.4%) | 15.60M -13.7M (-46.7%) | 4.92% +1.074 pp | 0.00% -0.001 pp | USD7.57 -53.0% | 41 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.02M -4.4K (-0.2%) | 7.20M -10.8M (-60.1%) | 2.27% -0.102 pp | 0.00% -0.001 pp | USD8.76 -59.4% | 41 qtrs — |
| 5 | TWO SIGMA INVESTMENTS, LP | 1.65M +616.7K (+59.5%) | 5.89M -3.3M (-36.2%) | 1.86% +0.643 pp | 0.01% -0.005 pp | USD4.99 -28.7% | 16 qtrs — |
| 6 | NWAM LLC | 870.8K -3.5K (-0.4%) | 4.37M -3.8M (-46.6%) | 1.02% -0.003 pp | 0.24% -0.200 pp | USD6.02 -40.9% | 12 qtrs — |
| 7 | TWO SIGMA ADVISERS, LP | 1.21M +451.1K (+59.5%) | 4.31M -2.4M (-36.2%) | 1.36% +0.470 pp | 0.01% -0.005 pp | USD5.22 -31.8% | 16 qtrs — |
| 8 | SUMMIT FINANCIAL, LLC | 903.4K +459.1K (+103.3%) | 3.22M -737.9K (-18.7%) | 1.01% +0.494 pp | 0.05% -0.013 pp | USD6.27 -43.2% | 3 qtrs — |
| 9 | GOLDMAN SACHS GROUP INC | 873.0K +569.6K (+187.7%) | 3.11M +407.6K (+15.1%) | 0.98% +0.625 pp | 0.00% +0.000 pp | USD4.94 -27.9% | 24 qtrs — |
| 10 | JANE STREET GROUP, LLC | 769.0K +550.7K (+252.4%) | 2.74M +795.3K (+41.0%) | 0.86% +0.608 pp | 0.00% +0.000 pp | USD5.08 -29.9% | 22 qtrs — |
| 11 | NORTHERN TRUST CORP | 738.2K -34.8K (-4.5%) | 2.63M -4.3M (-61.8%) | 0.83% -0.076 pp | 0.00% -0.001 pp | USD5.70 -37.5% | 41 qtrs — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 669.0K -48.4K (-6.7%) | 2.38M -4.0M (-62.7%) | 0.75% -0.089 pp | 0.00% -0.001 pp | USD12.45 -71.4% | 28 qtrs — |
| 13 | LPL FINANCIAL LLC | 528.8K -5.5K (-1.0%) | 1.88M -2.9M (-60.4%) | 0.59% -0.032 pp | 0.00% -0.001 pp | USD8.98 -60.4% | 19 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 524.2K +353.3K (+206.7%) | 1.87M +345.2K (+22.7%) | 0.59% +0.389 pp | 0.00% +0.000 pp | USD4.90 -27.3% | 41 qtrs — |
| 15 | BARCLAYS PLC | 493.2K +338.0K (+217.8%) | 1.76M +874.3K (+99.2%) | 0.55% +0.372 pp | 0.00% +0.000 pp | USD5.06 -29.6% | 28 qtrs — |
| 16 | MORGAN STANLEY | 474.9K -85.3K (-15.2%) | 1.69M -3.3M (-66.1%) | 0.53% -0.123 pp | 0.00% 0.000 pp | USD8.50 -58.1% | 41 qtrs — |
| 17 | UBS GROUP AG | 459.4K -32.6K (-6.6%) | 1.64M -2.7M (-62.6%) | 0.52% -0.060 pp | 0.00% 0.000 pp | USD9.33 -61.8% | 41 qtrs — |
| 18 | PRIVATE ADVISOR GROUP, LLC | 419.8K -35.3K (-7.8%) | 1.49M -2.6M (-63.1%) | 0.47% -0.062 pp | 0.01% -0.013 pp | USD8.94 -60.2% | 16 qtrs — |
| 19 | QUBE RESEARCH & TECHNOLOGIES LTD | 388.7K +388.7K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.44% +0.437 pp | 0.00% +0.001 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 20 | FEDERATED HERMES, INC. | 367.8K +367.8K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.41% +0.413 pp | 0.00% +0.002 pp | USD3.56 +0.0% | 3 qtrs — |
| 21 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 364.5K -332.9K (-47.7%) | 1.30M -4.9M (-79.1%) | 0.41% -0.407 pp | 0.00% -0.001 pp | USD9.08 -60.8% | 41 qtrs — |
| 22 | CAPTION MANAGEMENT, LLC | 354.8K +354.8K (+100.0%) | 1.26M +1.3M (+100.0%) | 0.40% +0.399 pp | 0.01% +0.009 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 23 | NATIONAL BANK OF CANADA /FI/ | 305.2K -88.0K (-22.4%) | 1.09M -2.4M (-68.9%) | 0.34% -0.118 pp | 0.00% -0.003 pp | USD8.68 -59.0% | 17 qtrs — |
| 24 | POINT72 ASSET MANAGEMENT, L.P. | 278.0K +278.0K (+100.0%) | 989.7K +989.7K (+100.0%) | 0.31% +0.312 pp | 0.00% +0.001 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 25 | WELLINGTON MANAGEMENT GROUP LLP | 272.2K -16.6K (-5.7%) | 969.1K -1.6M (-62.3%) | 0.31% -0.033 pp | 0.00% 0.000 pp | USD9.89 -64.0% | 5 qtrs — |
| 26 | BANK OF NEW YORK MELLON CORP | 244.1K -4.0K (-1.6%) | 868.8K -1.3M (-60.6%) | 0.27% -0.016 pp | 0.00% 0.000 pp | USD8.43 -57.8% | 41 qtrs — |
| 27 | CITADEL ADVISORS LLC | 222.1K +141.6K (+175.9%) | 790.7K +74.2K (+10.4%) | 0.25% +0.155 pp | 0.00% +0.000 pp | USD5.42 -34.3% | 37 qtrs — |
| 28 | PVG ASSET MANAGEMENT CORP | 216.3K +83.1K (+62.4%) | 770.0K -415.0K (-35.0%) | 0.25% +0.098 pp | 1.64% -2.725 pp | USD7.25 -50.9% | 6 qtrs — |
| 29 | MARSHALL WACE, LLP | 182.2K +— (+0.0%) | 648.6K -972.9K (-60.0%) | 0.20% -0.009 pp | 0.00% -0.001 pp | USD10.25 -65.3% | 7 qtrs — |
| 30 | NUVEEN, LLC | 168.4K +— (+0.0%) | 599.4K -899.1K (-60.0%) | 0.19% -0.008 pp | 0.00% 0.000 pp | USD8.58 -58.5% | 4 qtrs — |
| 31 | SWISS NATIONAL BANK | 164.4K +— (+0.0%) | 585.3K -877.9K (-60.0%) | 0.18% -0.008 pp | 0.00% -0.001 pp | USD8.58 -58.5% | 4 qtrs — |
| 32 | UBS ASSET MANAGEMENT AMERICAS INC | 162.1K +71.0 (+0.0%) | 577.2K -865.1K (-60.0%) | 0.18% -0.008 pp | 0.00% 0.000 pp | USD8.94 -60.2% | 4 qtrs — |
| 33 | RAFFERTY ASSET MANAGEMENT, LLC | 156.3K +47.9K (+44.2%) | 556.4K -408.6K (-42.3%) | 0.18% +0.049 pp | 0.00% -0.001 pp | USD6.66 -46.5% | 20 qtrs — |
| 34 | SCULPTOR CAPITAL LP | 155.9K +— (+0.0%) | 555.0K -832.5K (-60.0%) | 0.18% -0.008 pp | 0.01% -0.011 pp | USD9.22 -61.4% | 8 qtrs — |
| 35 | GSA CAPITAL PARTNERS LLP | 155.9K +92.8K (+147.1%) | 555.0K -6.0K (-1.1%) | 0.18% +0.101 pp | 0.05% +0.001 pp | USD5.72 -37.8% | 8 qtrs — |
| 36 | AQR CAPITAL MANAGEMENT LLC | 149.8K +121.8K (+434.4%) | 533.3K +283.8K (+113.7%) | 0.17% +0.135 pp | 0.00% +0.000 pp | USD3.94 -9.6% | 24 qtrs — |
| 37 | DIADEMA PARTNERS LP | 140.6K +800.0 (+0.6%) | 500.5K -743.7K (-59.8%) | 0.16% -0.006 pp | 0.09% -0.232 pp | USD8.87 -59.9% | 2 qtrs — |
| 38 | APELLA CAPITAL, LLC | 138.0K +38.5K (+38.7%) | 491.3K -405.4K (-45.2%) | 0.16% +0.045 pp | 0.01% -0.010 pp | USD7.18 -50.4% | 4 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 133.8K +20.0K (+17.5%) | 476.4K -537.0K (-53.0%) | 0.15% +0.017 pp | 0.00% 0.000 pp | USD7.18 -50.4% | 41 qtrs — |
| 40 | SHEETS SMITH WEALTH MANAGEMENT | 117.7K +117.7K (+100.0%) | 419.0K +419.0K (+100.0%) | 0.14% +0.138 pp | 0.05% +0.046 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 41 | 180 WEALTH ADVISORS, LLC | 117.4K +74.3K (+172.8%) | 417.9K +34.9K (+9.1%) | 0.14% +0.087 pp | 0.05% +0.001 pp | USD5.56 -36.0% | 4 qtrs — |
| 42 | ALLIANCEBERNSTEIN L.P. | 115.2K +— (+0.0%) | 410.1K -615.2K (-60.0%) | 0.13% -0.006 pp | 0.00% 0.000 pp | USD13.44 -73.5% | 24 qtrs — |
| 43 | RHUMBLINE ADVISERS | 107.4K -16.6K (-13.4%) | 382.3K -721.2K (-65.4%) | 0.12% -0.025 pp | 0.00% -0.001 pp | USD8.17 -56.4% | 27 qtrs — |
| 44 | STIFEL FINANCIAL CORP | 101.0K +49.2K (+95.1%) | 359.6K -101.3K (-22.0%) | 0.11% +0.053 pp | 0.00% 0.000 pp | USD6.16 -42.2% | 4 qtrs — |
| 45 | XTX TOPCO LTD | 99.1K +17.4K (+21.2%) | 352.6K -374.5K (-51.5%) | 0.11% +0.016 pp | 0.01% -0.029 pp | USD7.96 -55.3% | 2 qtrs — |
| 46 | CANADA PENSION PLAN INVESTMENT BOARD | 95.9K +95.9K (+100.0%) | 341.4K +341.4K (+100.0%) | 0.11% +0.108 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 47 | ENVESTNET ASSET MANAGEMENT INC | 87.7K +27.7K (+46.3%) | 312.1K -221.4K (-41.5%) | 0.10% +0.028 pp | 0.00% 0.000 pp | USD6.40 -44.4% | 6 qtrs — |
| 48 | LEGAL & GENERAL GROUP PLC | 86.9K +35.0 (+0.0%) | 309.7K -463.4K (-59.9%) | 0.10% -0.004 pp | 0.00% 0.000 pp | USD8.88 -59.9% | 27 qtrs — |
| 49 | HIKARI POWER LTD | 85.6K +— (+0.0%) | 305.0K -457.0K (-60.0%) | 0.10% +0.000 pp | 0.02% -0.037 pp | USD2.64 +34.8% | 29 qtrs — |
| 50 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 78.0K -350.0 (-0.4%) | 277.7K -419.7K (-60.2%) | 0.09% -0.004 pp | 0.00% 0.000 pp | USD8.44 -57.8% | 27 qtrs — |
| 51 | ALPS ADVISORS INC | 73.4K +34.8K (+90.0%) | 261.2K -82.4K (-24.0%) | 0.08% +0.037 pp | 0.00% 0.000 pp | USD8.47 -58.0% | 17 qtrs — |
| 52 | CREATIVE PLANNING | 72.7K -4.4K (-5.7%) | 259.0K -427.5K (-62.3%) | 0.08% -0.009 pp | 0.00% 0.000 pp | USD9.00 -60.4% | 17 qtrs — |
| 53 | FRANKLIN RESOURCES INC | 72.6K -302.7K (-80.7%) | 258.3K -10.8M (-97.7%) | 0.08% -0.358 pp | 0.00% -0.003 pp | USD8.39 -57.6% | 11 qtrs — |
| 54 | DEUTSCHE BANK AG\ | 69.5K -3.1K (-4.3%) | 247.6K -399.2K (-61.7%) | 0.08% -0.004 pp | 0.00% 0.000 pp | USD10.33 -65.5% | 41 qtrs — |
| 55 | AMERIPRISE FINANCIAL INC | 68.5K -17.3K (-20.1%) | 243.9K -519.6K (-68.1%) | 0.08% -0.024 pp | 0.00% 0.000 pp | USD8.29 -57.1% | 26 qtrs — |
| 56 | GLADSTONE INSTITUTIONAL ADVISORY LLC | 68.5K +9.0K (+15.1%) | 243.9K -285.9K (-54.0%) | 0.08% +0.007 pp | 0.01% -0.011 pp | USD8.96 -60.3% | 5 qtrs — |
| 57 | CARNEGIE CAPITAL ASSET MANAGEMENT, LLC | 67.6K -15.2K (-18.4%) | 240.6K -496.1K (-67.3%) | 0.08% -0.018 pp | 0.00% -0.009 pp | USD8.74 -59.3% | 13 qtrs — |
| 58 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 64.9K +21.1K (+48.2%) | 231.2K -158.7K (-40.7%) | 0.08% +0.025 pp | 0.00% 0.000 pp | USD7.35 -51.6% | 19 qtrs — |
| 59 | PNC FINANCIAL SERVICES GROUP, INC. | 63.7K -341.0 (-0.5%) | 226.7K -343.1K (-60.2%) | 0.07% -0.004 pp | 0.00% 0.000 pp | USD7.59 -53.1% | 19 qtrs — |
| 60 | SIG BROKERAGE, LP | 62.0K +— (+0.0%) | 220.7K -331.1K (-60.0%) | 0.07% -0.003 pp | 0.01% -0.009 pp | USD8.85 -59.8% | 4 qtrs — |
| 61 | PROFUND ADVISORS LLC | 58.0K +34.1K (+142.6%) | 206.4K -6.3K (-3.0%) | 0.07% +0.040 pp | 0.01% -0.001 pp | USD5.21 -31.7% | 12 qtrs — |
| 62 | JPMORGAN CHASE & CO | 56.5K +11.5K (+25.5%) | 201.3K -199.8K (-49.8%) | 0.07% +0.013 pp | 0.00% +0.000 pp | USD9.09 -60.8% | 27 qtrs — |
| 63 | SQUAREPOINT OPS LLC | 56.4K +56.4K (+100.0%) | 200.7K +200.7K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 14 qtrs — |
| 64 | FOSTER VICTOR WEALTH ADVISORS, LLC | 39.9K -553.0 (-1.4%) | 200.0K -203.1K (-50.4%) | 0.05% -0.001 pp | 0.01% -0.013 pp | USD9.11 -60.9% | 26 qtrs — |
| 65 | MAN GROUP PLC | 55.2K +30.8K (+126.5%) | 196.6K -20.4K (-9.4%) | 0.06% +0.034 pp | 0.00% +0.000 pp | USD5.92 -39.9% | 2 qtrs — |
| 66 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 54.7K +37.5K (+217.7%) | 194.8K +41.5K (+27.1%) | 0.06% +0.041 pp | 0.00% +0.001 pp | USD5.24 -32.1% | 4 qtrs — |
| 67 | INDEPENDENT ADVISOR ALLIANCE | 50.1K +2.3K (+4.8%) | 178.3K -247.1K (-58.1%) | 0.06% +0.003 pp | 0.00% -0.007 pp | USD7.84 -54.6% | 12 qtrs — |
| 68 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 47.9K +3.8K (+8.7%) | 172.8K -218.1K (-55.8%) | 0.05% +0.002 pp | 0.00% 0.000 pp | USD4.48 -20.5% | 7 qtrs — |
| 69 | GENEOS WEALTH MANAGEMENT INC. | 48.2K +5.8K (+13.7%) | 171.6K -205.8K (-54.5%) | 0.06% +0.007 pp | 0.00% -0.005 pp | USD6.90 -48.4% | 30 qtrs — |
| 70 | PRICE T ROWE ASSOCIATES INC /MD/ | 46.3K +669.0 (+1.5%) | 165.0K -241.0K (-59.4%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD8.31 -57.2% | 38 qtrs — |
| 71 | OCTOBER EFFECT LTD | 46.3K -198.9K (-81.1%) | 164.8K -2.0M (-92.5%) | 0.05% -0.233 pp | 0.18% -2.224 pp | USD9.05 -60.7% | 3 qtrs — |
| 72 | SCHONFELD STRATEGIC ADVISORS LLC | 46.2K +46.2K (+100.0%) | 164.5K +164.5K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.001 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 73 | QUANTINNO CAPITAL MANAGEMENT LP | 45.7K +11.4K (+33.4%) | 162.7K -142.3K (-46.7%) | 0.05% +0.011 pp | 0.00% -0.001 pp | USD7.43 -52.1% | 4 qtrs — |
| 74 | INVESCO LTD. | 45.5K -11.2K (-19.8%) | 161.9K -342.7K (-67.9%) | 0.05% -0.015 pp | 0.00% 0.000 pp | USD10.23 -65.2% | 23 qtrs — |
| 75 | D. E. SHAW & CO., INC. | 45.0K +45.0K (+100.0%) | 160.2K +160.2K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 76 | CETERA INVESTMENT ADVISERS | 42.9K +14.6K (+51.7%) | 152.6K -98.9K (-39.3%) | 0.05% +0.015 pp | 0.00% 0.000 pp | USD7.52 -52.7% | 5 qtrs — |
| 77 | SNOWDEN CAPITAL ADVISORS LLC | 42.7K +42.7K (+100.0%) | 152.1K +152.1K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.004 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 78 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 39.5K -2.2K (-5.3%) | 140.7K -230.7K (-62.1%) | 0.04% -0.005 pp | 0.00% 0.000 pp | USD10.40 -65.8% | 27 qtrs — |
| 79 | MARINER, LLC | 38.8K +12.5K (+47.3%) | 138.2K -96.4K (-41.1%) | 0.04% +0.013 pp | 0.00% 0.000 pp | USD7.19 -50.5% | 2 qtrs — |
| 80 | OPUS CAPITAL GROUP, LLC | 37.7K +3.0K (+8.6%) | 134.0K -175.0K (-56.6%) | 0.04% +0.004 pp | 0.01% -0.020 pp | USD8.61 -58.7% | 22 qtrs — |
| 81 | JANUS HENDERSON GROUP PLC | 37.0K +— (+0.0%) | 131.9K -197.2K (-59.9%) | 0.04% -0.002 pp | 0.00% 0.000 pp | USD8.58 -58.5% | 4 qtrs — |
| 82 | INTECH INVESTMENT MANAGEMENT LLC | 36.9K +— (+0.0%) | 131.5K -197.3K (-60.0%) | 0.04% -0.002 pp | 0.00% -0.002 pp | USD8.37 -57.5% | 6 qtrs — |
| 83 | METLIFE INVESTMENT MANAGEMENT, LLC | 35.7K -8.9K (-19.9%) | 127.2K -269.8K (-68.0%) | 0.04% -0.012 pp | 0.00% -0.001 pp | USD8.90 -60.0% | 23 qtrs — |
| 84 | LMR PARTNERS LLP | 35.2K +35.2K (+100.0%) | 125.3K +125.3K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 85 | WALLEYE CAPITAL LLC | 35.0K +35.0K (+100.0%) | 124.6K +124.6K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 86 | CHOREO, LLC | 32.0K -957.0 (-2.9%) | 121.6K -171.7K (-58.5%) | 0.04% -0.001 pp | 0.00% -0.002 pp | USD8.79 -59.5% | 4 qtrs — |
| 87 | BANK OF MONTREAL /CAN/ | 32.4K +9.5K (+41.3%) | 115.5K -88.8K (-43.5%) | 0.04% +0.010 pp | 0.00% +0.000 pp | USD5.67 -37.2% | 12 qtrs — |
| 88 | ADVISOR GROUP HOLDINGS, INC. | 31.7K -10.7K (-25.2%) | 113.0K -287.1K (-71.8%) | 0.04% -0.014 pp | 0.00% 0.000 pp | USD9.44 -62.3% | 24 qtrs — |
| 89 | FORUM FINANCIAL MANAGEMENT, LP | 30.1K +— (+0.0%) | 107.3K -160.9K (-60.0%) | 0.04% +0.000 pp | 0.00% -0.002 pp | USD8.58 -58.5% | 6 qtrs — |
| 90 | HSBC HOLDINGS PLC | 28.8K +28.8K (+100.0%) | 103.6K +103.6K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 1 qtrs NEW |
| 91 | NEWEDGE ADVISORS, LLC | 28.2K +26.6K (+1,636.2%) | 100.5K +86.0K (+594.5%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD3.89 -8.5% | 3 qtrs — |
| 92 | DIMENSIONAL FUND ADVISORS LP | 27.2K +27.2K (+100.0%) | 96.9K +96.9K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD3.56 +0.0% | 9 qtrs — |
| 93 | CITIGROUP INC | 25.6K +14.2K (+123.2%) | 91.3K -11.0K (-10.7%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD5.57 -36.1% | 39 qtrs — |
| 94 | AXQ CAPITAL, LP | 25.0K +5.9K (+30.9%) | 89.0K -81.0K (-47.7%) | 0.03% +0.007 pp | 0.02% -0.045 pp | USD7.64 -53.4% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 63 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.12% | 253.0K | 0.50% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 775.1K | 0.60% |
| 3 | iShares U.S. Small-Cap Equity Factor ETF SMLF | 0.03% | 1.04M | 0.15% |
| 4 | iShares Biotechnology ETF IBB | 0.02% | 1.61M | 0.44% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.02% | 188.0K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 12.6K | 0.35% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.02% | 73.7K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.02% | 11.9K | 0.19% |
| 9 | Vanguard Russell 2000 Growth ETF VTWG | 0.01% | 246.2K | 0.06% |
| 10 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.82M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
137.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+137,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | Paeger Axel | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-06 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 8.58 | 1.07M | 125,000 | D | ↗ |
| 2026-01-06 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 8.58 | 107.3K | 12,500 | D | ↗ |
| 2025-10-02 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.36 | 670.0K | 250,000 | D | ↗ |
| 2025-10-02 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 5.36 | 67.0K | 25,000 | D | ↗ |
| 2025-09-11 | MISSLING CHRISTOPHER U | Director / Officer | M-Exempt | A | Common Stock | 187,500 | 5.04 | 945.0K | 1,655,213 | D | ↗ |
| 2025-08-20 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 8.58 | 1.07M | 125,000 | D | ↗ |
| 2025-08-20 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 8.58 | 107.3K | 12,500 | D | ↗ |
| 2025-06-05 | Thomas Steffen | Director | M-Exempt | A | Common stock | 50,000 | 1.76 | 88.0K | 55,000 | D | ↗ |
| 2025-04-28 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 8.57 | 1.07M | 125,000 | D | ↗ |
| 2025-04-28 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 8.57 | 107.1K | 12,500 | D | ↗ |
| 2025-03-31 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.58 | 429.0K | 50,000 | D | ↗ |
| 2025-03-31 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.58 | 429.0K | 50,000 | D | ↗ |
| 2025-03-31 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.58 | 429.0K | 50,000 | D | ↗ |
| 2025-03-31 | Ma Jiong | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.58 | 429.0K | 50,000 | D | ↗ |
| 2025-03-31 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.58 | 429.0K | 50,000 | D | ↗ |
| 2025-03-24 | MISSLING CHRISTOPHER U | Director / Officer | M-Exempt | A | Common Stock | 500,000 | 0.92 | 460.0K | 1,750,210 | D | ↗ |
| 2025-01-15 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 166,666 | 7.54 | 1.26M | 166,000 | D | ↗ |
| 2025-01-15 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 8.57 | 107.1K | 12,500 | D | ↗ |
| 2024-12-19 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 5.36 | 670.0K | 125,000 | D | ↗ |
| 2024-12-19 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 12,500 | 5.36 | 67.0K | 12,500 | D | ↗ |
| 2024-11-19 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 10.09 | 1.26M | 250,000 | D | ↗ |
| 2024-11-19 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.09 | 100.9K | 20,000 | D | ↗ |
| 2024-06-14 | Donhauser Peter D.O. | Director | P-Purchase | A | Common Stock | 2,835 | 3.64 | 10.3K | 5,000 | — | ↗ |
| 2024-05-15 | Thomas Steffen | Director | P-Purchase | A | Common Stock | 5,000 | 4.52 | 22.6K | 5,000 | — | ↗ |
| 2024-03-28 | MISSLING CHRISTOPHER U | Director / Officer | M-Exempt | A | Common Stock | 73,380 | 1.32 | 96.9K | 1,323,590 | — | ↗ |
| 2024-02-20 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.36 | 268.0K | 50,000 | — | ↗ |
| 2024-02-20 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.36 | 268.0K | 50,000 | — | ↗ |
| 2024-02-20 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.36 | 268.0K | 50,000 | — | ↗ |
| 2024-02-20 | Ma Jiong | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.36 | 268.0K | 50,000 | — | ↗ |
| 2024-02-20 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.36 | 268.0K | 50,000 | — | ↗ |
| 2024-01-02 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | D | Stock Option (Right to Buy) | 125,000 | 10.09 | 1.26M | 125,000 | — | ↗ |
| 2024-01-02 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.09 | 100.9K | 10,000 | — | ↗ |
| 2023-06-29 | MISSLING CHRISTOPHER U | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 232,000 | 1.60 | 371.2K | 0 | — | ↗ |
| 2023-06-28 | MISSLING CHRISTOPHER U | Director / Officer | S-Sale | D | Common Stock | 268,000 | 7.98 | 2.14M | 1,018,210 | — | ↗ |
| 2023-03-31 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.57 | 428.5K | 50,000 | — | ↗ |
| 2023-03-31 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.57 | 428.5K | 50,000 | — | ↗ |
| 2023-03-31 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.57 | 428.5K | 50,000 | — | ↗ |
| 2023-03-31 | Ma Jiong | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.57 | 428.5K | 50,000 | — | ↗ |
| 2023-03-31 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.57 | 428.5K | 50,000 | — | ↗ |
| 2022-06-27 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-27 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-27 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-27 | Ma Jiong | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-27 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 10.09 | 504.5K | 50,000 | — | ↗ |
| 2022-05-25 | Skarpelos Athanasios | Director | S-Sale | D | Common Stock | 50,000 | 9.06 | 453.0K | 1,306,458 | — | ↗ |
| 2021-08-02 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.11 | 452.8K | 25,000 | — | ↗ |
| 2021-08-02 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.11 | 452.8K | 25,000 | — | ↗ |
| 2021-08-02 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.11 | 452.8K | 25,000 | — | ↗ |
| 2021-08-02 | Ma Jiong | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.11 | 452.8K | 25,000 | — | ↗ |
| 2021-08-02 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 18.11 | 9.06M | 500,000 | — | ↗ |
| 2021-08-02 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.11 | 452.8K | 25,000 | — | ↗ |
| 2021-08-02 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 18.11 | 724.4K | 40,000 | — | ↗ |
| 2021-06-29 | MISSLING CHRISTOPHER U | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 51,620 | 1.32 | 68.1K | 73,380 | — | ↗ |
| 2021-06-29 | Boenisch Sandra | Officer | M-Exempt | A | Common Stock | 106,696 | 3.28 | 350.0K | 154,659 | — | ↗ |
| 2021-06-02 | Ma Jiong | Director | — | D | Stock Option (Right to Buy) | 35,000 | 13.01 | 455.4K | 0 | — | ↗ |
| 2021-05-21 | FAVUS ELLIOT | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,500 | 5.66 | 8.5K | 0 | — | ↗ |
| 2021-05-17 | Donhauser Peter D.O. | Director | P-Purchase | A | Common Stock | 1,000 | 10.93 | 10.9K | 2,165 | — | ↗ |
| 2021-02-24 | FAVUS ELLIOT | Director | M-Exempt | D | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 0 | — | ↗ |
| 2021-02-19 | Donhauser Peter D.O. | Director | P-Purchase | A | Common Stock | 165 | 12.97 | 2.1K | 1,165 | — | ↗ |
| 2020-12-30 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.49 | 192.2K | 35,000 | — | ↗ |
| 2020-12-30 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.49 | 192.2K | 35,000 | — | ↗ |
| 2020-12-30 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.49 | 192.2K | 35,000 | — | ↗ |
| 2020-12-30 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 5.49 | 3.02M | 550,000 | — | ↗ |
| 2020-12-30 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.49 | 192.2K | 35,000 | — | ↗ |
| 2020-12-30 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.49 | 192.2K | 35,000 | — | ↗ |
| 2020-12-30 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.49 | 274.5K | 50,000 | — | ↗ |
| 2020-01-06 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2020-01-06 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2020-01-06 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2020-01-06 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 2.96 | 1.63M | 550,000 | — | ↗ |
| 2020-01-06 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2020-01-06 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.96 | 148.0K | 50,000 | — | ↗ |
| 2020-01-06 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 2.96 | 207.2K | 70,000 | — | ↗ |
| 2019-06-04 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.93 | 102.6K | 35,000 | — | ↗ |
| 2019-05-03 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 3.15 | 2.36M | 750,000 | — | ↗ |
| 2018-10-01 | Velden Claus Vander | Director | A-Award | A | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 45,500 | — | ↗ |
| 2018-10-01 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 45,500 | — | ↗ |
| 2018-10-01 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 45,500 | — | ↗ |
| 2018-10-01 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 409,500 | 2.58 | 1.06M | 409,500 | — | ↗ |
| 2018-10-01 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 45,500 | — | ↗ |
| 2018-10-01 | Donhauser Peter D.O. | Director | A-Award | A | Stock Option (Right to Buy) | 45,500 | 2.58 | 117.4K | 45,500 | — | ↗ |
| 2018-10-01 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 27,300 | 2.58 | 70.4K | 27,300 | — | ↗ |
| 2018-05-15 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 2.30 | 1.04M | 450,000 | — | ↗ |
| 2018-05-15 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.30 | 69.0K | 30,000 | — | ↗ |
| 2018-03-07 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 1,360 | 2.92 | 4.0K | 1,018,210 | — | ↗ |
| 2018-03-06 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 1,450 | 2.73 | 4.0K | 1,016,850 | — | ↗ |
| 2018-03-05 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 1,500 | 2.63 | 3.9K | 1,015,400 | — | ↗ |
| 2018-03-02 | Velden Claus Vander | Director | — | D | Stock Option (Right to Buy) | 50,000 | 2.60 | 130.0K | 0 | — | ↗ |
| 2018-03-02 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 1,650 | 2.41 | 4.0K | 1,013,900 | — | ↗ |
| 2017-12-13 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 3.30 | 1.32M | 400,000 | — | ↗ |
| 2017-12-13 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.30 | 99.0K | 30,000 | — | ↗ |
| 2017-10-25 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.39 | 1.6K | 1,012,250 | — | ↗ |
| 2017-10-24 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.92 | 1.8K | 1,011,875 | — | ↗ |
| 2017-10-19 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.49 | 1.7K | 1,011,500 | — | ↗ |
| 2017-10-17 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.27 | 1.6K | 1,011,125 | — | ↗ |
| 2017-10-13 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 750 | 4.22 | 3.2K | 1,010,750 | — | ↗ |
| 2017-10-05 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.30 | 1.6K | 1,010,000 | — | ↗ |
| 2017-10-02 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.20 | 1.6K | 1,009,625 | — | ↗ |
| 2017-09-28 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.21 | 1.6K | 1,009,250 | — | ↗ |
| 2017-09-26 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 3.88 | 1.5K | 1,008,875 | — | ↗ |
| 2017-09-20 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.23 | 1.6K | 1,008,500 | — | ↗ |
| 2017-09-18 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.40 | 1.7K | 1,008,125 | — | ↗ |
| 2017-09-14 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.58 | 1.7K | 1,007,750 | — | ↗ |
| 2017-09-11 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.81 | 1.8K | 1,007,375 | — | ↗ |
| 2017-09-07 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.76 | 1.8K | 1,007,000 | — | ↗ |
| 2017-09-05 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.90 | 1.8K | 1,006,625 | — | ↗ |
| 2017-08-31 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.48 | 1.7K | 1,006,250 | — | ↗ |
| 2017-08-28 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.44 | 1.7K | 1,005,875 | — | ↗ |
| 2017-08-24 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.54 | 1.7K | 1,005,500 | — | ↗ |
| 2017-08-21 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 4.07 | 1.5K | 1,005,125 | — | ↗ |
| 2017-08-18 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 3.81 | 1.4K | 1,004,750 | — | ↗ |
| 2017-08-14 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 375 | 3.70 | 1.4K | 1,004,375 | — | ↗ |
| 2017-08-11 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common Stock | 750 | 3.55 | 2.7K | 1,004,000 | — | ↗ |
| 2017-05-12 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 5.92 | 2.66M | 450,000 | — | ↗ |
| 2017-05-12 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 5.92 | 207.2K | 35,000 | — | ↗ |
| 2017-02-08 | Donhauser Peter D.O. | Director | — | D | Stock Option (Right to Buy) | 50,000 | 5.39 | 269.5K | 0 | — | ↗ |
| 2016-09-22 | Thomas Steffen | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.28 | 328.0K | 100,000 | — | ↗ |
| 2016-09-22 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.28 | 328.0K | 100,000 | — | ↗ |
| 2016-09-22 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 3.28 | 1.64M | 500,000 | — | ↗ |
| 2016-09-22 | METZNER BERND | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.28 | 328.0K | 100,000 | — | ↗ |
| 2016-09-22 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.28 | 328.0K | 100,000 | — | ↗ |
| 2016-09-22 | Boenisch Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 106,696 | 3.28 | 350.0K | 106,696 | — | ↗ |
| 2016-07-18 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 861,429 | 7.06 | 6.08M | 861,429 | — | ↗ |
| 2016-07-05 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 379,625 | 6.26 | 2.38M | 379,625 | — | ↗ |
| 2016-06-30 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 6.11 | 9.2K | 1,500 | — | ↗ |
| 2016-04-27 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 5.66 | 8.5K | 1,500 | — | ↗ |
| 2016-03-31 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 4.90 | 7.4K | 1,500 | — | ↗ |
| 2015-12-31 | FAVUS ELLIOT | Director | A-Award | A | Stock Option/Right to Buy | 4,500 | 1.68 | 7.6K | 92,000 | — | ↗ |
| 2015-10-01 | Boenisch Sandra | Officer | — | D | Stock Option (Right to Buy) | 100,000 | 1.42 | 142.0K | 0 | — | ↗ |
| 2015-09-30 | FAVUS ELLIOT | Director | A-Award | A | Stock Option (Right to Buy) | 1,500 | 5.64 | 8.5K | 1,500 | — | ↗ |
| 2015-09-18 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock option | 187,500 | 5.04 | 945.0K | 187,500 | — | ↗ |
| 2015-07-14 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.52 | 518.40 | 4,013,000 | — | ↗ |
| 2015-07-13 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.53 | 529.50 | 4,012,000 | — | ↗ |
| 2015-07-07 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.51 | 509.90 | 4,011,000 | — | ↗ |
| 2015-07-06 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.47 | 469.50 | 4,010,000 | — | ↗ |
| 2015-07-01 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.45 | 454.80 | 3,009,000 | — | ↗ |
| 2015-06-30 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.44 | 444.60 | 3,008,000 | — | ↗ |
| 2015-06-23 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.47 | 468.00 | 3,007,000 | — | ↗ |
| 2015-06-22 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.42 | 415.00 | 3,006,000 | — | ↗ |
| 2015-06-16 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.44 | 442.00 | 3,005,000 | — | ↗ |
| 2015-06-15 | Thomas Steffen | Director | — | D | Stock Option (Right to Buy) | 200,000 | 0.42 | 84.0K | 0 | — | ↗ |
| 2015-06-15 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.43 | 428.00 | 3,004,000 | — | ↗ |
| 2015-06-10 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.36 | 355.00 | 3,003,000 | — | ↗ |
| 2015-06-08 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.35 | 352.00 | 3,002,000 | — | ↗ |
| 2015-06-04 | MISSLING CHRISTOPHER U | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.37 | 368.50 | 3,001,000 | — | ↗ |
| 2015-04-02 | Skarpelos Athanasios | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.92 | 46.0K | 50,000 | — | ↗ |
| 2015-04-02 | MISSLING CHRISTOPHER U | Director / Officer | A-Award | A | Stock option | 500,000 | 0.92 | 460.0K | 500,000 | — | ↗ |
| 2015-04-02 | METZNER BERND | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.92 | 46.0K | 87,500 | — | ↗ |
| 2015-04-02 | FAVUS ELLIOT | Director | A-Award | A | Stock Option/Right to Buy | 50,000 | 0.92 | 46.0K | 87,500 | — | ↗ |
| 2014-05-07 | METZNER BERND | Director | — | D | Stock Option (Right to Buy) | 150,000 | 0.30 | 45.0K | 0 | — | ↗ |
| 2014-05-07 | FAVUS ELLIOT | Director | — | D | Stock Option (Right to Buy) | 150,000 | 0.30 | 45.0K | 0 | — | ↗ |
| 2013-11-28 | Skarpelos Athanasios | Director / 10% Owner | G-Gift | D | Common Stock | 300,000 | 0.00 | — | 5,225,832 | — | ↗ |
| 2013-10-29 | Skarpelos Athanasios | Director / 10% Owner | G-Gift | D | Common Stock | 200,000 | 0.00 | — | 5,525,832 | — | ↗ |
| 2013-10-01 | Skarpelos Athanasios | Director / 10% Owner | G-Gift | D | Common Stock | 1,000,000 | 0.00 | — | 5,725,832 | — | ↗ |
| 2013-07-05 | MISSLING CHRISTOPHER U | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2012-10-10 | TIDMARSH GEORGE F | Director / Officer | — | D | stock options | 500,000 | 1.50 | 750.0K | 0 | — | ↗ |
| 2012-05-29 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 8,572 | 1.05 | 9.0K | 550,000 | — | ↗ |
| 2012-05-24 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 10,000 | 0.80 | 8.0K | 558,572 | — | ↗ |
| 2012-02-24 | Lowry William Sean | Director | — | D | stock options | 150,000 | 3.72 | 558.0K | 0 | — | ↗ |
| 2012-02-09 | TIDMARSH GEORGE F | Director / Officer | J-Other | A | common stock | 8,000 | 1.25 | 10.0K | 8,000 | — | ↗ |
| 2011-06-15 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 3,000 | 2.84 | 8.5K | 571,572 | — | ↗ |
| 2011-06-14 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 3,200 | 2.90 | 9.3K | 574,572 | — | ↗ |
| 2011-06-13 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 2,100 | 3.05 | 6.4K | 577,772 | — | ↗ |
| 2011-05-13 | Chisholm John Robert | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-04-14 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 10,000 | 2.75 | 27.5K | 579,872 | — | ↗ |
| 2011-03-10 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 5,500 | 3.68 | 20.2K | 589,872 | — | ↗ |
| 2011-02-18 | Lalach Harvey | Director / Officer | S-Sale | D | common stock | 3,000 | 3.75 | 11.3K | 597,000 | — | ↗ |
| 2011-02-03 | Durrant Cameron | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-09-01 | Tousley David L. | Director | A-Award | A | stock options | 200,000 | 3.45 | 690.0K | 400,000 | — | ↗ |
| 2010-06-29 | Tousley David L. | Director | A-Award | A | stock options | 50,000 | 3.50 | 175.0K | 200,000 | — | ↗ |
| 2010-06-29 | Lalach Harvey | Director / Officer | A-Award | A | stock options | 50,000 | 3.50 | 175.0K | 200,000 | — | ↗ |
| 2010-06-29 | Durrant Cameron | Director | A-Award | A | stock options | 50,000 | 3.50 | 175.0K | 1,000,000 | — | ↗ |
| 2010-06-29 | Ayers Alison E. | Director | A-Award | A | stock options | 50,000 | 3.50 | 175.0K | 200,000 | — | ↗ |
| 2010-06-12 | KERGROHEN HERVE DE | Officer | — | D | stock options | 700,000 | 2.25 | 1.58M | 0 | — | ↗ |
| 2010-03-26 | Tousley David L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-03-26 | Lalach Harvey | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-03-26 | Durrant Cameron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-03-26 | Ayers Alison E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-10-29 | Skarpelos Athanasios | 10% Owner | S-Sale | D | common stock | 111,112 | 2.25 | 250.0K | 6,725,832 | — | ↗ |
| 2009-08-08 | Skarpelos Athanasios | 10% Owner | S-Sale | D | common stock | 111,112 | 2.25 | 250.0K | 6,836,944 | — | ↗ |
| 2009-06-29 | Skarpelos Athanasios | 10% Owner | S-Sale | D | common stock | 619,444 | 2.25 | 1.39M | 6,948,056 | — | ↗ |
| 2009-06-18 | Durrant Cameron | Director | J-Other | D | common stock | 75,000 | 0.00 | — | 0 | — | ↗ |
| 2009-05-13 | Durrant Cameron | Director | A-Award | A | stock options | 400,000 | 2.50 | 1.00M | 950,000 | — | ↗ |
| 2008-06-03 | Tousley David L. | Director | — | D | Stock Option | 150,000 | 5.00 | 750.0K | 0 | — | ↗ |
| 2008-06-03 | Lalach Harvey | Director / Officer | A-Award | A | Stock Options | 150,000 | 5.00 | 750.0K | 150,000 | — | ↗ |
| 2008-06-03 | Ayers Alison E. | Director | A-Award | A | Stock Options | 150,000 | 5.00 | 750.0K | 150,000 | — | ↗ |
| 2008-05-20 | Durrant Cameron | Director | A-Award | A | stock options | 400,000 | 5.25 | 2.10M | 550,000 | — | ↗ |
| 2008-05-20 | Ayers Alison E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-12-03 | Durrant Cameron | Director | — | D | Stock Option | 150,000 | 3.85 | 577.5K | 0 | — | ↗ |
| 2007-10-26 | Skarpelos Athanasios | 10% Owner | S-Sale | D | Common shares | 950,000 | 1.70 | 1.62M | 7,567,500 | — | ↗ |
| 2007-09-17 | Skarpelos Athanasios | 10% Owner | P-Purchase | A | Common Shares | 92,500 | 3.60 | 333.0K | 8,517,500 | — | ↗ |
| 2007-07-30 | Skarpelos Athanasios | 10% Owner | S-Sale | D | common shares | 950,000 | 1.70 | 1.62M | 8,425,000 | — | ↗ |
| 2007-02-08 | Vernadaki Angela | Officer | P-Purchase | A | Stock Option | 150,000 | 3.00 | 450.0K | 150,000 | — | ↗ |
| 2007-02-08 | Kontzalis Panos | Director / Officer | P-Purchase | A | Stock Option | 200,000 | 3.00 | 600.0K | 200,000 | — | ↗ |
| 2007-02-08 | Kalkanis George | Officer | P-Purchase | A | Stock Option | 150,000 | 3.00 | 450.0K | 150,000 | — | ↗ |
| 2007-02-07 | Vernadaki Angela | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-02-07 | Kalkanis George | Officer | — | D | Common | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2007-01-31 | Vamvakides Alexandre | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-01-25 | Kontzalis Panos | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
92.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Christopher Missling President, Chief Executive Officer and Director | 700.0K | 140.0K | — | 1.93M | — | 16.1K | 2.78M | 69.25% | ↗ |
| 2 | 2024 | Sandra Boenisch Principal Financial Officer and Treasurer | 201.5K | — | — | 192.7K | — | 8.1K | 402.2K | 47.91% | ↗ |
| 3 | 2023 | Christopher Missling President, Chief Executive Officer and Director | 700.0K | 124.8K | — | 3.07M | — | 3.5K | 3.89M | 78.73% | ↗ |
| 4 | 2023 | Sandra Boenisch Principal Financial Officer and Treasurer | 186.9K | — | — | 306.7K | — | 7.5K | 501.1K | 61.21% | ↗ |
| 5 | 2022 | Christopher Missling President, Chief Executive Officer and Director | 586.4K | 110.0K | — | 6.05M | — | 12.2K | 6.75M | 89.51% | ↗ |
| 6 | 2022 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 586.4K | 110.0K | — | 6.05M | — | 12.2K | 6.75M | 89.51% | ↗ |
| 7 | 2022 | Sandra Boenisch Principal Financial Officer and Treasurer | 174.9K | — | — | 277.6K | — | — | 452.5K | 61.35% | ↗ |
| 8 | 2021 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 550.0K | 110.0K | — | 8.75M | — | 11.6K | 9.42M | 92.87% | ↗ |
| 9 | 2021 | Christopher Missling President, Chief Executive Officer and Director | 550.0K | 110.0K | — | 8.75M | — | 11.6K | 9.42M | 92.87% | ↗ |
| 10 | 2021 | Sandra Boenisch Principal Financial Officer and Treasurer | 158.3K | — | — | 724.3K | — | — | 882.6K | 82.06% | ↗ |
| 11 | 2020 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 550.0K | 55.0K | — | 1.22M | — | 11.4K | 1.84M | 66.52% | ↗ |
| 12 | 2020 | Sandra Boenisch Principal Financial Officer and Treasurer | 117.0K | 22.3K | — | 155.9K | — | — | 295.2K | 52.80% | ↗ |
| 13 | 2019 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 512.5K | 50.0K | — | 2.81M | — | 11.2K | 3.38M | 83.03% | ↗ |
| 14 | 2019 | Sandra Boenisch Principal Financial Officer and Treasurer | 72.3K | 13.6K | — | 138.7K | — | — | 224.6K | 61.75% | ↗ |
| 15 | 2018 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 500.0K | 65.0K | — | 1.97M | — | — | 2.55M | 77.41% | ↗ |
| 16 | 2018 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 500.0K | 65.0K | — | 1.97M | — | — | 2.54M | 77.75% | ↗ |
| 17 | 2018 | Sandra Boenisch Principal Financial Officer and Treasurer | 79.6K | 11.4K | — | 141.0K | — | — | 232.1K | 60.78% | ↗ |
| 18 | 2018 | Sandra Boenisch Principal Financial Officer | 79.6K | 11.4K | — | 141.0K | — | — | 232.1K | 60.78% | ↗ |
| 19 | 2017 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 500.0K | — | — | 2.29M | — | — | 2.79M | 82.05% | ↗ |
| 20 | 2017 | Sandra Boenisch Principal Financial Officer and Treasurer | 71.8K | — | — | 177.8K | — | — | 249.6K | 71.23% | ↗ |
| 21 | 2017 | Sandra Boenisch Principal Financial Officer | 71.8K | — | — | 177.8K | — | — | 249.6K | 71.23% | ↗ |
| 22 | 2016 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 305.0K | — | — | 8.50M | — | 2.29M | 11.09M | 76.60% | ↗ |
| 23 | 2016 | Christopher Missling, PhD. President, Chief Executive Officer, Chief Financial Officer and Director | 305.0K | — | — | 8.50M | — | 2.29M | 11.09M | 76.60% | ↗ |
| 24 | 2016 | Sandra Boenisch Principal Financial Officer | 58.0K | — | — | 407.4K | — | — | 465.4K | 87.53% | ↗ |
| 25 | 2016 | Sandra Boenisch Principal Financial Officer and Treasurer | 58.0K | — | — | 407.4K | — | — | 465.4K | 87.54% | ↗ |
| 26 | 2015 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 240.0K | — | 1.22M | 1.15M | — | 1.13M | 3.74M | 63.41% | ↗ |
| 27 | 2015 | Christopher Missling, PhD. President, Chief Executive Officer, Chief Financial Officer and Director | 240.0K | — | 1.22M | 1.15M | — | 1.13M | 3.74M | 63.41% | ↗ |
| 28 | 2015 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 240.0K | — | 1.22M | 1.15M | — | 1.13M | 3.74M | 63.41% | ↗ |
| 29 | 2015 | Sandra Boenisch Principal Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 30 | 2015 | Sandra Boenisch Principal Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 31 | 2014 | Christopher Missling, PhD. President, Chief Executive Officer, Chief Financial Officer and Director | 240.0K | 400.0K | — | 127.8K | — | — | 767.8K | 16.64% | ↗ |
| 32 | 2014 | Christopher Missling, PhD President, Chief Executive Officer, and Director | 240.0K | 400.0K | — | 127.8K | — | — | 767.8K | 16.64% | ↗ |
| 33 | 2014 | Sandra Boenisch Principal Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 34 | 2008 | Panos Kontzalis Former CEO | 127.5K | — | 340.6K | — | — | 71.5K | 539.6K | 63.12% | ↗ |
| 35 | 2008 | Harvey Lalach President, CFO and Secretary | 111.5K | — | — | 264.7K | — | — | 376.2K | 70.36% | ↗ |
| 36 | 2008 | Alexandre Vamvakides Chief Scientific Officer | 113.4K | — | — | — | — | — | 113.4K | 0.00% | ↗ |
| 37 | 2007 | Panos Kontzalis Former CEO | 136.0K | — | — | — | — | — | 136.0K | 0.00% | ↗ |
| 38 | 2007 | Panos Kontzalis CEO | 136.0K | — | — | — | — | — | 136.0K | 0.00% | ↗ |
| 39 | 2007 | Harvey Lalach President, CFO and Secretary | 56.0K | — | — | — | — | — | 56.0K | 0.00% | ↗ |
| 40 | 2007 | Alexandre Vamvakides Chief Scientific Officer | 48.0K | — | — | — | — | — | 48.0K | 0.00% | ↗ |
| 41 | 2007 | Panos Kontzalis CEO Director | 34.0K | — | — | — | — | — | 34.0K | 0.00% | ↗ |
| 42 | 2007 | George Kalkanis VP Strategic Planning | 15.0K | — | — | — | — | — | 15.0K | 0.00% | ↗ |
| 43 | 2007 | Harvey Lalach President, CFO, Secretary Director | 14.0K | — | — | — | — | — | 14.0K | 0.00% | ↗ |
| 44 | 2007 | Alexandre Vamvakides Chief Scientific Officer Director | 12.0K | — | — | — | — | — | 12.0K | 0.00% | ↗ |
| 45 | 2006 | Harvey Lalach President, CFO and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 46 | 2006 | Panos Kontzalis Former CEO | — | — | — | — | — | — | — | — | ↗ |
| 47 | 2006 | Panos Kontzalis CEO | — | — | — | — | — | — | — | — | ↗ |
| 48 | 2006 | Alexandre Vamvakides Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 49 | 2005 | Alexandre Vamvakides Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 50 | 2005 | Harvey Lalach President, CFO and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 51 | 2005 | Panos Kontzalis CEO | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher U. Missling | President, Chief Executive Officer, Secretary & Director | 876.1K | — |
| Sandra Boenisch | Principal Financial Officer & Treasurer | 247.1K | female |
| Juan Carlos Lopez-Talavera | Senior Vice President & Head of Research and Development | — | — |
| Kun Jin | Vice President & Head of Biostatistics | — | — |
| Terrie Kellmeyer | Interim Chief Executive Officer | — | — |
| Adebayo Laniyonu | Senior Vice President of Nonclinical Development | — | — |
| Wolfgang Liedtke | Senior VP & Global Head of Neurology | — | — |
| Clint Tomlinson | Vice President of Corporate | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVXL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
